SIGLEC12 and graft versus host disease: Finally, KEGG pathway enrichment further supported this trend, with high SIGLEC12 expression linked to diseases and processes involving hyperactive immune responses such as graft-versus-host disease, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and cytokine–cytokine receptor interactions.